[go: up one dir, main page]

AU2001236042A1 - Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell - Google Patents

Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Info

Publication number
AU2001236042A1
AU2001236042A1 AU2001236042A AU2001236042A AU2001236042A1 AU 2001236042 A1 AU2001236042 A1 AU 2001236042A1 AU 2001236042 A AU2001236042 A AU 2001236042A AU 2001236042 A AU2001236042 A AU 2001236042A AU 2001236042 A1 AU2001236042 A1 AU 2001236042A1
Authority
AU
Australia
Prior art keywords
cell
culture
vaccine
serum
usable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001236042A
Other versions
AU2001236042B9 (en
AU2001236042B2 (en
Inventor
Yoichiro Kino
Keiichi Makizumi
Kanako Masuda
Sachio Tokiyoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority claimed from PCT/JP2001/001599 external-priority patent/WO2001064846A1/en
Publication of AU2001236042A1 publication Critical patent/AU2001236042A1/en
Application granted granted Critical
Publication of AU2001236042B2 publication Critical patent/AU2001236042B2/en
Publication of AU2001236042B9 publication Critical patent/AU2001236042B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001236042A 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell Ceased AU2001236042B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000059262 2000-03-03
JP2000-59262 2000-03-03
PCT/JP2001/001599 WO2001064846A1 (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Publications (3)

Publication Number Publication Date
AU2001236042A1 true AU2001236042A1 (en) 2001-11-22
AU2001236042B2 AU2001236042B2 (en) 2006-01-12
AU2001236042B9 AU2001236042B9 (en) 2006-06-29

Family

ID=18579742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001236042A Ceased AU2001236042B9 (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU3604201A Pending AU3604201A (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3604201A Pending AU3604201A (en) 2000-03-03 2001-03-02 Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Country Status (9)

Country Link
US (1) US6825036B2 (en)
EP (1) EP1260581B1 (en)
JP (1) JP4698112B2 (en)
KR (1) KR100797547B1 (en)
AT (1) ATE473272T1 (en)
AU (2) AU2001236042B9 (en)
CA (1) CA2401117C (en)
DE (1) DE60142506D1 (en)
WO (1) WO2001064846A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144903A1 (en) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Replication of virus in cell cultures, useful for preparing vaccines and diagnostic reagents, where replication of cells and virus is simultaneous
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
CA2592120A1 (en) 2004-12-23 2006-07-06 Medimmune Vaccines, Inc. Non-tumorigenic mdck cell line for propagating viruses
EP1862537B1 (en) * 2005-03-10 2013-05-08 Kyoritsu Seiyaku Corporation Cell line culturable without aminal-derived component, method for establishment thereof, method for production of virus using the cell line and method for production of vaccine
FR2884255B1 (en) 2005-04-11 2010-11-05 Vivalis USE OF EBX AVIATION STEM CELL LINES FOR THE PRODUCTION OF INFLUENZA VACCINE
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
CA2627971A1 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
CN102755645A (en) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 Influenza vaccines with reduced amount of emulsion adjuvant
NZ567981A (en) 2005-11-04 2011-10-28 Novartis Vaccines & Diagnostic Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514841A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Influenza vaccine comprising a combination of particulate adjuvant and immunopotentiator
CA2628158C (en) 2005-11-04 2015-12-15 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
PL2478916T3 (en) 2006-01-27 2020-11-16 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2007132763A1 (en) * 2006-05-11 2007-11-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for proliferation of influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2497495B3 (en) * 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2069480B1 (en) * 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN101971030A (en) 2007-12-24 2011-02-09 诺华有限公司 Assays for adsorbed influenza vaccines
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
TW201012930A (en) * 2008-06-16 2010-04-01 Intervet Int Bv Method of replicating viruses in suspension
JP5689796B2 (en) 2008-08-01 2015-03-25 ガマ ワクチンズ ピーティワイ リミテッド Influenza vaccine
US8202726B2 (en) 2008-09-24 2012-06-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
JP2012517416A (en) 2009-02-10 2012-08-02 ノバルティス アーゲー Influenza vaccine with increased amount of H3 antigen
EA201171032A1 (en) 2009-02-10 2012-02-28 Новартис Аг TREATMENT SCHEMES WITH THE HELP OF VACCINE AGAINST FLU, ASSOCIATED WITH PANDEMIC STRAINS
JP5642712B2 (en) 2009-02-10 2014-12-17 ノバルティス アーゲー Influenza vaccine with low amounts of squalene
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
BRPI1011432A2 (en) 2009-05-08 2019-09-24 Novartis Ag Generic Assays for Influenza Virus Detection
EP2573184A1 (en) 2009-05-21 2013-03-27 Novartis AG Reverse genetics using non-endogenous POL I promoters
CN102666860B (en) 2009-07-31 2015-06-17 诺华股份有限公司 Reverse genetics systems
CN102695523A (en) 2009-09-10 2012-09-26 诺华有限公司 Combination vaccines against respiratory tract diseases
EP2491117B2 (en) 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
EP2545172B2 (en) 2010-03-08 2017-12-06 Novartis AG Methods of testing for intracellular pathogens
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
AU2011249487C1 (en) 2010-05-06 2015-05-14 Novartis Ag Organic peroxide compounds for microorganism inactivation
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
KR20130081659A (en) 2010-06-01 2013-07-17 노파르티스 아게 Concentration of vaccine antigens with lyophilization
EP2575872B1 (en) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012033236A1 (en) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 Mdck cell line adapted to serum-free culture and suspension culture, and method for preparing viruses for vaccine using cells thereof
CA2812135A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
CA2858794A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assays for influenza virus hemagglutinins
JP6054883B2 (en) 2012-03-02 2016-12-27 ノバルティス アーゲー Influenza virus reassembly
AU2013270793A1 (en) 2012-06-04 2014-12-11 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
MX2015006927A (en) 2012-12-03 2016-02-05 Novartis Ag Reassortant influenza a viren.
CN103045530B (en) * 2012-12-14 2015-06-17 山东滨州沃华生物工程有限公司 Method for suspension culturing cell
ES2808673T3 (en) 2012-12-28 2021-03-01 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
WO2014105672A1 (en) * 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
KR101370512B1 (en) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 Mdck-derived cell lines suspension-cultured in a protein-free medium and method for propagating virus using the same
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN111896742B (en) 2015-07-07 2024-08-06 思齐乐 Influenza efficacy test
EP3368665A4 (en) 2015-10-30 2019-08-28 National Health Research Institutes MDCK CELL LINES IN SUSPENSION IN CHEMICALLY DEFINED SERUM-FREE MEDIA FOR VACCINE PRODUCTION
CN105567628B (en) * 2016-01-30 2019-07-12 令世鑫 A kind of low blood serum medium of the full culture mdck cell that suspends
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
KR102453351B1 (en) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) Method for manufacture of Influenza Working Virus Seed Stock
JP2021500891A (en) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション Recombinant influenza virus with stabilized HA for replication in eggs
CN108265024B (en) * 2018-03-30 2022-02-18 吉林冠界生物技术有限公司 Serum-free medium suitable for MDCK cell full-suspension culture and preparation method thereof
WO2020041311A1 (en) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
CN109609436A (en) * 2018-11-09 2019-04-12 中农威特生物科技股份有限公司 A kind of no CO2The preparation method of the mdck cell of environment suspension serum-free cell system entirely
US20220080040A1 (en) 2018-12-21 2022-03-17 Intervet Inc. Serum free intracellular pathogen vaccine
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (en) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
KR20220152226A (en) * 2020-02-11 2022-11-15 사이토누스 테라퓨틱스, 인크. Rapid Vaccine Platform
WO2021261892A1 (en) * 2020-06-22 2021-12-30 코오롱생명과학 주식회사 Method for mass-producing vaccinia virus by using suspension cells
CN114317405B (en) * 2021-12-21 2023-08-29 广东省华晟生物技术有限公司 Serum-free full-suspension culture type F81 cell line and construction method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348877A (en) 1993-03-12 1994-09-20 Boyce Thompson Institute For Plant Research, Inc. Method of adapting anchorage-dependent cell lines to suspension conditions
FR2726574B1 (en) 1994-11-04 1997-01-17 Univ Paris Curie PROCESS FOR DISSOCIATION OF EUKARYOTIC CELLS IN CULTURE
ATE429246T1 (en) * 1994-11-10 2009-05-15 Baxter Healthcare Sa METHOD FOR PRODUCING BIOLOGICAL PRODUCTS IN PROTEIN-FREE CULTURE
DE19612966B4 (en) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process

Similar Documents

Publication Publication Date Title
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
AU2722997A (en) Influenza virus replicated in mammalian cell culture and vaccine production
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
IL161858A0 (en) Cell culture process
AU2002336930A1 (en) Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture
AU2002225781A1 (en) Microincubator cell culture apparatus including transparent heater
HUP0203386A3 (en) Magnetic glass particles, method for their preparation and uses thereof
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
ZA200404101B (en) In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
AU2001294577A1 (en) Methods for preparing interferon producing dentitric cells
AU2002221033A1 (en) Cells to be used in producing virus vector, process for producing the same and process for producing virus vector with the use of the cells
HUP0105126A2 (en) High construction precipitated silicic acids, using them and process for producing them
HK1048650A1 (en) Methods for enhancing the production of cytokines in cell cultur e
AU2003207288A1 (en) Anterior ocular-associated cell sheet, three-dimensional construct and process for producing the same
AU2001269445A1 (en) Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same
IL162343A0 (en) Cell constructs cultured in vitro, preparation anduses
AU2002221526A1 (en) Method for producing vital, biological substitute tissue in vitro using cell cultures and a support
AU2001234616A1 (en) Vaccine composition, process and methods
AU4771600A (en) Cells, culture methods and their uses
AU2001252591A1 (en) Novel promoters and gene expression method by using the promoters
GB2397819B (en) (R)-Hydroxycarboxylic acid producing recombinant microorganism and process for preparing (R)-hydroxycarboxylic acid using the same
AU2001254864A1 (en) Cell culture method, cell cluster obtained by said methods and use thereof
AU7456101A (en) Process for producing hexafluoroethane and use thereof
AU2001242750A1 (en) Novel protein, process for producing the same and use thereof
AU3673500A (en) Fine particles targeting cells and process for producing the same